Press Releases BioVaxys Technology Corp. OTC Markets

Equities

BVAXF

CA09076M1014

Delayed OTC Markets Other stock markets 17:37:35 16/07/2024 BST			5-day change	1st Jan Change
0.045 ^USD	-13.35%		-14.29%	+9.76%

07-10	BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI
07-10	BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canadian Investment Regulatory Organization Trade Resumption - BIOV	03:21pm	AQ
BioVaxys Technology Corp. Announces Revocation of Cease Trade Order	07-12	AQ
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order	05-16	AQ
CSE Bulletin: Suspension - BioVaxys Technology Corp. (BIOV)	05-16	NE
Canadian Investment Regulatory Organization Trading Halt - BIOV	05-16	AQ
BioVaxys Technology Corp. Closes SECOND Tranche of Private Placement	05-10	AQ
BioVaxys Technology Corp. Closes First Tranche of Private Placement	05-03	AQ
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	05-02	AQ
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050	05-01	AQ
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	04-18	AQ
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY	04-10	AQ
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	04-05	AQ
BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT	03-22	AQ
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	03-21	AQ
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	03-07	AQ
Annual Financial Statements Update for the Year Ended October 31, 2023	02-21	AQ
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.	02-21	AQ
Canadian Investment Regulatory Organization Trade Resumption - BIOV	02-12	AQ
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.	02-12	AQ
Canadian Investment Regulatory Organization Trading Halt - BIOV	02-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioVaxys Technology Corp. OTC Markets

Equities

BVAXF

CA09076M1014

Press Releases

Filters